Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic

Gonda Fj Konings1,2, Karlijn Mc Cornel1,2, Sofia Xanthoulea1,2

  • 1GROW - School for Oncology and Developmental Biology, Maastricht University, The Netherlands.

The Journal of Pathology
|November 17, 2017
PubMed

Insights

Inhibiting the enzyme 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD-1) effectively blocks the production of active estrogen (17β-estradiol) from estrone in endometrial cancer models. This finding supports 17β-HSD-1 as a potential therapeutic target for endometrial cancer.

Area of Science:

  • Endocrinology
  • Oncology
  • Biochemistry

Background:

  • Type 1 17β-hydroxysteroid dehydrogenase (17β-HSD-1) is overexpressed in endometrial cancer (EC), increasing intra-tissue generation of 17β-estradiol (E2).
  • This increased E2 production is implicated in the estrogen-dependent progression of EC.

Purpose of the Study:

  • To investigate the inhibition of 17β-HSD-1 to impair E2 generation from estrone (E1) in EC.
  • To evaluate the therapeutic potential of targeting 17β-HSD-1 in various EC models.

Main Methods:

  • Generated EC cell lines with similar 17β-HSD-1 levels to human tissues.
  • Utilized in vitro (cell culture), in vivo (chicken chorioallantoic membrane model), and ex vivo (patient tumor tissues) approaches.
  • Employed High-Performance Liquid Chromatography (HPLC) for enzyme activity assessment and specific 17β-HSD-1 inhibitors.

Main Results:

  • 17β-HSD-1 activity was successfully blocked by a specific inhibitor in EC cells.
  • Inhibition of 17β-HSD-1 impaired E1-induced colony formation in vitro and E1-driven cyclin A upregulation in vivo.
  • Ex vivo analysis confirmed 17β-HSD-1 enzyme activity in primary EC tissues, with significant inhibition observed in over 45% of samples.

Conclusions:

  • 17β-HSD-1 inhibition effectively blocks E2 generation from E1 across diverse EC models.
  • The study demonstrates the presence and inhibition of 17β-HSD-1 activity in primary and metastatic EC.
  • Further preclinical development of 17β-HSD-1 inhibitors is warranted for potential human studies in EC treatment.